MX2010005262A - Compuestos que contienen quinoxalina como inhibidores del virus de hepatitis c. - Google Patents
Compuestos que contienen quinoxalina como inhibidores del virus de hepatitis c.Info
- Publication number
- MX2010005262A MX2010005262A MX2010005262A MX2010005262A MX2010005262A MX 2010005262 A MX2010005262 A MX 2010005262A MX 2010005262 A MX2010005262 A MX 2010005262A MX 2010005262 A MX2010005262 A MX 2010005262A MX 2010005262 A MX2010005262 A MX 2010005262A
- Authority
- MX
- Mexico
- Prior art keywords
- hepatitis
- present
- compounds
- virus
- quinoxaline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención describe compuestos de la Fórmula I y II o sales, ésteres, o promedicamentos farmacéuticamente aceptables, de los mismos que inhiben la actividad serina proteasa, en particular la actividad de proteasa NS3-NS4A del virus de la hepatitis C (VHC ). En consecuencia, los compuestos de la presente invención interfieren con el ciclo de vida del virus de la hepatitis C y también son útiles como agentes antivirales. La presente invención se relaciona además con composiciones farmacéuticas que comprenden los compuestos antes mencionados para administrar a un sujeto que sufre de infección por VHC. La invención también se relaciona con métodos para tratar una infección por VHC en un sujeto mediante la administración de una composición farmacéutica que comprende los compuestos de la presente invención. (VER FORMULA).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98795807P | 2007-11-14 | 2007-11-14 | |
| US2545808P | 2008-02-01 | 2008-02-01 | |
| PCT/US2008/083541 WO2009064975A1 (en) | 2007-11-14 | 2008-11-14 | Quinoxaline-containing compounds as hepatitis c virus inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010005262A true MX2010005262A (es) | 2010-08-10 |
Family
ID=40639146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010005262A MX2010005262A (es) | 2007-11-14 | 2008-11-14 | Compuestos que contienen quinoxalina como inhibidores del virus de hepatitis c. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8324155B2 (es) |
| EP (1) | EP2219453B1 (es) |
| JP (1) | JP5479354B2 (es) |
| KR (1) | KR20100098527A (es) |
| CN (1) | CN101909446A (es) |
| AR (1) | AR069464A1 (es) |
| AU (1) | AU2008322537A1 (es) |
| BR (1) | BRPI0820085A2 (es) |
| CA (1) | CA2705807A1 (es) |
| CL (1) | CL2008003384A1 (es) |
| CO (1) | CO6280441A2 (es) |
| CR (1) | CR11499A (es) |
| DO (1) | DOP2010000143A (es) |
| EC (1) | ECSP10010254A (es) |
| ES (1) | ES2476257T3 (es) |
| HK (1) | HK1146693A1 (es) |
| IL (1) | IL205611A0 (es) |
| MX (1) | MX2010005262A (es) |
| MY (1) | MY155851A (es) |
| PE (2) | PE20091212A1 (es) |
| RU (1) | RU2493160C2 (es) |
| TW (1) | TWI431011B (es) |
| UA (1) | UA102677C2 (es) |
| UY (1) | UY31470A1 (es) |
| WO (1) | WO2009064975A1 (es) |
| ZA (1) | ZA201003363B (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006242475B2 (en) | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
| NZ565269A (en) | 2005-08-01 | 2010-03-26 | Merck & Co Inc | Macrocyclic peptides as HCV NS3 protease inhibitors |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| EP2076278B1 (en) | 2006-10-24 | 2015-05-06 | Merck Sharp & Dohme Corp. | Macrocyclic HCV NS3 protease inhibitors |
| EP2079479B1 (en) | 2006-10-24 | 2014-11-26 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| AU2007318164B2 (en) | 2006-10-27 | 2013-02-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| RU2468029C2 (ru) | 2006-10-27 | 2012-11-27 | Иституто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти С.П.А. | Ингибиторы hcv ns3 протеазы |
| EP2121707B1 (en) | 2006-12-20 | 2012-12-05 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Antiviral indoles |
| GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| JP2010533699A (ja) | 2007-07-17 | 2010-10-28 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Ｃ型肝炎感染症の治療のための大環状インドール誘導体 |
| AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| US8030307B2 (en) * | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
| WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
| WO2009079352A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Macrocyclic oximyl hepatitis c serine protease inhibitors |
| US8283309B2 (en) | 2007-12-20 | 2012-10-09 | Enanta Pharmaceuticals, Inc. | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors |
| JP2011510927A (ja) | 2008-01-24 | 2011-04-07 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖセリンプロテアーゼ阻害剤としての二フッ素化トリペプチド |
| AU2009241445A1 (en) | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| WO2009134987A1 (en) * | 2008-04-30 | 2009-11-05 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors |
| NZ590638A (en) | 2008-07-22 | 2012-06-29 | Merck Sharp & Dohme | MACROCYCLIC QUINOXALINE COMPOUNDS AS Hepatitis C Virus NS3 PROTEASE INHIBITORS |
| WO2010132163A1 (en) * | 2009-05-13 | 2010-11-18 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| WO2011049908A2 (en) * | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
| SG188957A1 (en) | 2010-01-25 | 2013-05-31 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| RU2535664C2 (ru) | 2010-01-27 | 2014-12-20 | Аб Фарма Лтд | Полигетероциклические соединения, используемые в качестве высокоэффективных ингибиторов вируса гепатита с |
| US9127021B2 (en) | 2010-04-09 | 2015-09-08 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| AR083052A1 (es) | 2010-09-21 | 2013-01-30 | Enanta Pharm Inc | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2012269643A1 (en) | 2011-06-16 | 2014-02-06 | AB Pharma Ltd. | Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof |
| AU2013270672B2 (en) | 2012-06-08 | 2017-10-19 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
| ES2656087T3 (es) | 2012-06-08 | 2018-02-23 | Gilead Sciences, Inc. | Inhibidores macrocíclicos de virus Flaviviridae |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| SG11201502802PA (en) | 2012-10-19 | 2015-05-28 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| KR102215400B1 (ko) | 2013-03-15 | 2021-02-10 | 길리애드 사이언시즈, 인코포레이티드 | C형 간염 바이러스의 마크로시클릭 및 비시클릭 억제제 |
| CA2934049A1 (en) * | 2013-12-23 | 2015-07-02 | Gilead Sciences, Inc. | Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide |
| WO2015100145A1 (en) | 2013-12-23 | 2015-07-02 | Gilead Sciences, Inc. | Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide |
| EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| CN107074876B (zh) * | 2016-04-08 | 2019-12-20 | 上海长森药业有限公司 | 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途 |
| CN107266529A (zh) * | 2016-04-08 | 2017-10-20 | 上海长森药业有限公司 | 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途 |
| RU2650610C1 (ru) * | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
| CN107987083A (zh) * | 2017-11-24 | 2018-05-04 | 江苏亚盛医药开发有限公司 | 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE419270T1 (de) | 2000-04-05 | 2009-01-15 | Schering Corp | Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| PA8603801A1 (es) * | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | Derivados de la quinazolina |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| AU2006242475B2 (en) | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
| EA019888B1 (ru) * | 2005-07-25 | 2014-07-30 | Интермьюн, Инк. | Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза |
| NZ565269A (en) * | 2005-08-01 | 2010-03-26 | Merck & Co Inc | Macrocyclic peptides as HCV NS3 protease inhibitors |
| GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| GB0612423D0 (en) * | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| AR061629A1 (es) | 2006-06-26 | 2008-09-10 | Enanta Pharm Inc | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| US7582605B2 (en) | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| RU2468029C2 (ru) * | 2006-10-27 | 2012-11-27 | Иституто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти С.П.А. | Ингибиторы hcv ns3 протеазы |
| US20080287449A1 (en) | 2007-04-26 | 2008-11-20 | Deqiang Niu | Aza-tripeptide hepatitis c serine protease inhibitors |
| US20080267917A1 (en) | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
| US8377872B2 (en) | 2007-04-26 | 2013-02-19 | Enanta Pharmaceuticals, Inc. | Cyclic P3 tripeptide hepatitis C serine protease inhibitors |
| AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| CA2705803A1 (en) | 2007-11-14 | 2009-05-22 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors |
| JP2011506329A (ja) | 2007-12-05 | 2011-03-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | キノキサリニル誘導体 |
| WO2009076173A2 (en) | 2007-12-05 | 2009-06-18 | Enanta Pharmaceuticals, Inc. | Fluorinated tripeptide hcv serine protease inhibitors |
| WO2009079352A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Macrocyclic oximyl hepatitis c serine protease inhibitors |
| WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
| US8283309B2 (en) | 2007-12-20 | 2012-10-09 | Enanta Pharmaceuticals, Inc. | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors |
-
2008
- 2008-11-13 CL CL2008003384A patent/CL2008003384A1/es unknown
- 2008-11-14 AR ARP080104983A patent/AR069464A1/es unknown
- 2008-11-14 PE PE2008001930A patent/PE20091212A1/es not_active Application Discontinuation
- 2008-11-14 EP EP08850226.5A patent/EP2219453B1/en not_active Not-in-force
- 2008-11-14 WO PCT/US2008/083541 patent/WO2009064975A1/en active Application Filing
- 2008-11-14 MY MYPI2010002236A patent/MY155851A/en unknown
- 2008-11-14 UA UAA201007220A patent/UA102677C2/uk unknown
- 2008-11-14 ES ES08850226.5T patent/ES2476257T3/es active Active
- 2008-11-14 TW TW097144049A patent/TWI431011B/zh active
- 2008-11-14 RU RU2010123928/04A patent/RU2493160C2/ru not_active IP Right Cessation
- 2008-11-14 MX MX2010005262A patent/MX2010005262A/es active IP Right Grant
- 2008-11-14 JP JP2010534203A patent/JP5479354B2/ja active Active
- 2008-11-14 PE PE2013001102A patent/PE20140189A1/es not_active Application Discontinuation
- 2008-11-14 CN CN2008801250191A patent/CN101909446A/zh active Pending
- 2008-11-14 CA CA2705807A patent/CA2705807A1/en not_active Abandoned
- 2008-11-14 US US12/271,144 patent/US8324155B2/en not_active Expired - Fee Related
- 2008-11-14 UY UY31470A patent/UY31470A1/es not_active Application Discontinuation
- 2008-11-14 KR KR1020107012702A patent/KR20100098527A/ko not_active Application Discontinuation
- 2008-11-14 BR BRPI0820085A patent/BRPI0820085A2/pt not_active IP Right Cessation
- 2008-11-14 AU AU2008322537A patent/AU2008322537A1/en not_active Abandoned
-
2010
- 2010-05-06 IL IL205611A patent/IL205611A0/en unknown
- 2010-05-12 ZA ZA2010/03363A patent/ZA201003363B/en unknown
- 2010-05-13 DO DO2010000143A patent/DOP2010000143A/es unknown
- 2010-06-09 CO CO10069276A patent/CO6280441A2/es active IP Right Grant
- 2010-06-14 CR CR11499A patent/CR11499A/es not_active Application Discontinuation
- 2010-06-14 EC EC2010010254A patent/ECSP10010254A/es unknown
-
2011
- 2011-02-25 HK HK11101918.4A patent/HK1146693A1/xx not_active IP Right Cessation
-
2012
- 2012-10-22 US US13/657,555 patent/US8951998B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010005262A (es) | Compuestos que contienen quinoxalina como inhibidores del virus de hepatitis c. | |
| MX2010006209A (es) | Derivados de quinoxalinilo. | |
| MX2010010276A (es) | Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c. | |
| WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
| MX2010006518A (es) | Inhibidores de serina proteasa de hepatitis c de oximil macrociclica. | |
| MX2010005261A (es) | Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo. | |
| WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
| WO2008021956A3 (en) | Acylaminoheteroaryl hepatitis c virus protease inhibitors | |
| WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
| WO2008019266A3 (en) | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors | |
| WO2007143694A3 (en) | Macrocyclic oximyl hepatitis c protease inhibitors | |
| MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
| MX2011012155A (es) | Compuestos macrociclicos como inhibidores del virus de hepatitis c. | |
| MX2019013037A (es) | Prolina macrociclica derivada de inhibidores de serina proteasa de vhc. | |
| WO2008021960A3 (en) | Triazolyl macrocyclic hepatitis c serine protease inhibitors | |
| WO2008021733A3 (en) | Tetrazolyl acyclic hepatitis c serine protease inhibitors | |
| WO2008019289A3 (en) | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors | |
| WO2008019303A3 (en) | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors | |
| WO2009053828A3 (en) | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors | |
| WO2008002924A3 (en) | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors | |
| WO2011049908A3 (en) | Bismacrokyclic compounds as hepatitis c virus inhibitors | |
| MY160130A (en) | Hepatitis c virus inhibitors | |
| MX2010008109A (es) | Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). | |
| TN2012000358A1 (en) | Hepatitis c virus inhibitors | |
| EP2555622A4 (en) | HEPATITIS C-VIRUS HEMMER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |